Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
99mTc-CNDG7 SPECT in Healthy Subjects and NSCLC Patients
ChiCTR2400083521Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of 99mTc-CN7DG in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Safety index. Planned start May 2024; status: not yet recruiting.
02
Drugs
99mTc-CN7DG
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400083521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083521.